Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, has announced the pricing of an underwritten public offering of 6,550,219 shares of its common stock at a public offering price of US$45.80 per share. Intellia also granted the underwriter a 30-day option to purchase up to an additional 982,532 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately US$300 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares in the offering are to be sold by Intellia. Goldman Sachs & Co. LLC is the sole underwriter for the offering. The offering is expected to close on or about December 2, 2022, subject to customary closing conditions.
Latham & Watkins LLP represents the underwriter in the offering with a capital markets team led by partners Nathan Ajiashvili and Peter Handrinos, with associates Sandy Kugbei, Egzon Sulejmani, and James Sullivan.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
The advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
